Related Experiment Videos
The management of hormone refractory prostate cancer
1Department of Urology, Vrije Universiteit, Amsterdam, The Netherlands.
Abstract:
Prostate cancer patients deemed unsuitable for curative therapy by means of radical prostatectomy or radiation are offered androgen ablation or suppression therapy, which normally results in an inhibition of prostate cellular growth for a period of 12-18 months. Death of patients from prostate cancer is directly related to the development of clones of cells capable of multiplying and metastasising without androgen stimulation, and to date efforts to suppress these cells have been singularly unsuccessful. There are a number of treatment options available, and these include secondary hormone therapy, growth factor inhibition, chemotherapy, combination therapies and interstitial radiotherapy. The merits and disadvantages of these management approaches are discussed.
Insights
Androgen deprivation therapy temporarily inhibits prostate cancer growth. However, treatment resistance develops due to androgen-independent cells, necessitating exploration of alternative therapies for advanced prostate cancer.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer patients unsuitable for surgery or radiation often receive androgen deprivation therapy (ADT).
- ADT typically inhibits tumor growth for 12-18 months.
- Therapy resistance and metastasis are linked to androgen-independent prostate cancer cells, posing a significant challenge.
Purpose of the Study:
- To review and discuss various treatment options for advanced prostate cancer.
- To evaluate the merits and disadvantages of secondary hormone therapy, growth factor inhibition, chemotherapy, combination therapies, and interstitial radiotherapy.
Main Methods:
- Literature review and discussion of existing treatment modalities for advanced prostate cancer.
- Comparative analysis of different therapeutic approaches based on available data.
Main Results:
- Androgen deprivation therapy offers temporary control but is ultimately limited by treatment resistance.
- Emergence of androgen-independent prostate cancer cells drives disease progression and metastasis.
- Several alternative treatment strategies exist, including secondary hormonal therapies, targeted agents, and radiation techniques.
Conclusions:
- Effective management of advanced prostate cancer requires addressing androgen-independent disease progression.
- A range of treatment options are available, each with specific benefits and drawbacks.
- Further research is needed to overcome treatment resistance and improve outcomes for patients with advanced prostate cancer.